It has been known that the coronaviruses SARS-CoV-2 and SARS-CoV use human ACE2 as the entry receptor and human proteases as the entry activators. The virus surface spike (S) protein mediates SARS-CoV-2 entry into cells. To fulfill its function, SARS-CoV-2 spike binds to the human ACE2 (hACE2) receptor through its receptor-binding domain (RBD) and is proteolytically activated by human proteases.
Our SARS-CoV-2 Pseudoviral Particles are replication-deficient MLV pseudotyped with the SARS-CoV-2 spike protein carrying the original D614 genotype (Genbank Accession # YP_009724390.1) of the original SARS-CoV-2 strain (the Wuhan-Hu-1 isolate. They also contain the ORF for firefly luciferase as a reporter. They establish a pseudovirus entry assay for SARS-CoV-2 as the spike protein mediated cell entry can be conveniently measured via the luciferase reporter activity. This pseudovirus assay isolates the SARS-CoV-2 viral entry from other steps of the viral infection cycle.
A related item, Catalog
MBS434278, is the SARS-CoV-2 virus pseudotyped with the 614G variant spike protein.
